Repare Therapeutics announces Gilead to acquire RP-3467 for up to $30M

Repare Therapeutics (RPTX) announced a definitive asset purchase agreement for Gilead Sciences (GILD) to acquire Repare’s polymerase theta ATPase inhibitor, RP-3467. Under the terms of the Gilead Agreement, Repare will receive up to $30 million in total consideration, including a $25 million upfront payment, subject to customary holdbacks and adjustments, and an additional $5 million payment upon completion of specified technology transfer activities. On November 14, 2025, Repare announced that it had entered into a definitive arrangement agreement with XenoTherapeutics and Xeno Acquisition, pursuant to which Xeno will acquire all of the issued and outstanding common shares of Repare. Under the terms of the Arrangement Agreement, Repare shareholders will receive a cash payment per Common Share that will be determined based upon Repare’s cash balance at closing of the Arrangement Transaction. The upfront portion of the consideration payable under the Gilead Agreement has increased Repare’s cash balance and, therefore, has also increased the estimated Closing Net Cash Amount. Based on Repare’s revised estimate of the Closing Net Cash Amount, it is now currently estimated that each Repare shareholder will receive a cash payment of approximately US$2.20 per Common Share at the Arrangement Closing.